FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944078873> ?p ?o ?g. }

• W2944078873 abstract "Pulmonary arterial hypertension (PAH) is a life-threatening disease that typically causes shortness of breath and exercise intolerance. Combination therapy with ambrisentan and tadalafil has proven to be more effective at preventing clinical failure events in patients with PAH than either drug alone. The aim of this study was to evaluate the bioequivalence of an ambrisentan/tadalafil fixed-dose combination (FDC) compared with co-administration of the 2 monotherapies.This 3-part, randomized, single-dose, open-label crossover study was conducted in healthy volunteers. The first part of the study consisted of a 5-way crossover that compared the relative bioavailability of 4 FDC formulations (10-mg ambrisentan + 40-mg tadalafil) with co-administered reference monotherapies. One formulation was selected and its relative bioavailability was assessed when produced in 3 different granulation sizes during the second part of the study. In the third part of the study, the bioequivalence of the candidate FDC with the reference monotherapies was evaluated for the 10-mg/40-mg dose strength, in addition to 2 other dose strengths (5 mg/20 mg and 5 mg/40 mg). For all parts of the study, blood samples were taken at regular intervals after each dose, ambrisentan and tadalafil concentrations determined, and pharmacokinetic (PK) parameters (Cmax, AUC0-∞, and AUC0-t) obtained. Test/reference ratios of the geometric means of PK parameters were used to evaluate bioequivalence. Safety and tolerability were assessed by recording adverse events and monitoring vital signs, ECGs, and clinical laboratory data.Of the 174 subjects screened for eligibility, 112 were allocated to a randomized treatment sequence across all study parts, and 100 completed their full assigned treatments. All 4 FDC formulations tested during part 1 of the study yielded PK parameters similar those of the reference treatments. In part 2, granulation size was found to not affect the relative bioavailability of the selected formulation. In part 3, the selected FDC was found to be bioequivalent to co-administration of the monotherapies in both the fasted and fed states. The FDC was also found to be bioequivalent to the reference treatments at the 2 additional dose strengths. All but one of the adverse events was mild to moderate in intensity, and no serious adverse events were reported.An ambrisentan/tadalafil FDC was bioequivalent to concurrently administered monotherapies and therefore represents a viable alternative treatment to co-administration. Use of an FDC is likely to be associated with reduced costs and improved patient compliance. ClinicalTrials.gov identifier: NCT02688387." @default.
• W2944078873 created "2019-05-16" @default.
• W2944078873 creator A5016048999 @default.
• W2944078873 creator A5021173247 @default.
• W2944078873 creator A5031512177 @default.
• W2944078873 creator A5034172795 @default.
• W2944078873 creator A5034352791 @default.
• W2944078873 creator A5062796971 @default.
• W2944078873 creator A5084959058 @default.
• W2944078873 creator A5089247044 @default.
• W2944078873 date "2019-06-01" @default.
• W2944078873 modified "2023-09-27" @default.
• W2944078873 title "A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects" @default.
• W2944078873 cites W1975119053 @default.
• W2944078873 cites W1984693219 @default.
• W2944078873 cites W1998921082 @default.
• W2944078873 cites W2001090735 @default.
• W2944078873 cites W2023607416 @default.
• W2944078873 cites W2039788472 @default.
• W2944078873 cites W2051069436 @default.
• W2944078873 cites W2056208776 @default.
• W2944078873 cites W2091862472 @default.
• W2944078873 cites W2093943199 @default.
• W2944078873 cites W2097382561 @default.
• W2944078873 cites W2106199142 @default.
• W2944078873 cites W2112229901 @default.
• W2944078873 cites W2125263078 @default.
• W2944078873 cites W2129125190 @default.
• W2944078873 cites W2141262339 @default.
• W2944078873 cites W2148038451 @default.
• W2944078873 cites W2151863430 @default.
• W2944078873 cites W2154951602 @default.
• W2944078873 cites W2158891637 @default.
• W2944078873 cites W2161370807 @default.
• W2944078873 cites W2162804111 @default.
• W2944078873 cites W2313158847 @default.
• W2944078873 cites W2431254231 @default.
• W2944078873 cites W2531336280 @default.
• W2944078873 cites W2764260555 @default.
• W2944078873 doi "https://doi.org/10.1016/j.clinthera.2019.04.007" @default.
• W2944078873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31060740" @default.
• W2944078873 hasPublicationYear "2019" @default.
• W2944078873 type Work @default.
• W2944078873 sameAs 2944078873 @default.
• W2944078873 citedByCount "1" @default.
• W2944078873 countsByYear W29440788732021 @default.
• W2944078873 crossrefType "journal-article" @default.
• W2944078873 hasAuthorship W2944078873A5016048999 @default.
• W2944078873 hasAuthorship W2944078873A5021173247 @default.
• W2944078873 hasAuthorship W2944078873A5031512177 @default.
• W2944078873 hasAuthorship W2944078873A5034172795 @default.
• W2944078873 hasAuthorship W2944078873A5034352791 @default.
• W2944078873 hasAuthorship W2944078873A5062796971 @default.
• W2944078873 hasAuthorship W2944078873A5084959058 @default.
• W2944078873 hasAuthorship W2944078873A5089247044 @default.
• W2944078873 hasConcept C112705442 @default.
• W2944078873 hasConcept C126322002 @default.
• W2944078873 hasConcept C126894567 @default.
• W2944078873 hasConcept C142724271 @default.
• W2944078873 hasConcept C144980905 @default.
• W2944078873 hasConcept C170493617 @default.
• W2944078873 hasConcept C181389837 @default.
• W2944078873 hasConcept C197934379 @default.
• W2944078873 hasConcept C204787440 @default.
• W2944078873 hasConcept C22979827 @default.
• W2944078873 hasConcept C27081682 @default.
• W2944078873 hasConcept C2776623344 @default.
• W2944078873 hasConcept C2778375690 @default.
• W2944078873 hasConcept C2779929075 @default.
• W2944078873 hasConcept C2780263000 @default.
• W2944078873 hasConcept C2780816001 @default.
• W2944078873 hasConcept C2781109936 @default.
• W2944078873 hasConcept C42404028 @default.
• W2944078873 hasConcept C71924100 @default.
• W2944078873 hasConcept C87813604 @default.
• W2944078873 hasConcept C98274493 @default.
• W2944078873 hasConceptScore W2944078873C112705442 @default.
• W2944078873 hasConceptScore W2944078873C126322002 @default.
• W2944078873 hasConceptScore W2944078873C126894567 @default.
• W2944078873 hasConceptScore W2944078873C142724271 @default.
• W2944078873 hasConceptScore W2944078873C144980905 @default.
• W2944078873 hasConceptScore W2944078873C170493617 @default.
• W2944078873 hasConceptScore W2944078873C181389837 @default.
• W2944078873 hasConceptScore W2944078873C197934379 @default.
• W2944078873 hasConceptScore W2944078873C204787440 @default.
• W2944078873 hasConceptScore W2944078873C22979827 @default.
• W2944078873 hasConceptScore W2944078873C27081682 @default.
• W2944078873 hasConceptScore W2944078873C2776623344 @default.
• W2944078873 hasConceptScore W2944078873C2778375690 @default.
• W2944078873 hasConceptScore W2944078873C2779929075 @default.
• W2944078873 hasConceptScore W2944078873C2780263000 @default.
• W2944078873 hasConceptScore W2944078873C2780816001 @default.
• W2944078873 hasConceptScore W2944078873C2781109936 @default.
• W2944078873 hasConceptScore W2944078873C42404028 @default.
• W2944078873 hasConceptScore W2944078873C71924100 @default.
• W2944078873 hasConceptScore W2944078873C87813604 @default.
• W2944078873 hasConceptScore W2944078873C98274493 @default.
• W2944078873 hasFunder F4320307773 @default.
• W2944078873 hasLocation W29440788731 @default.
• W2944078873 hasLocation W29440788732 @default.

• next